It is noteworthy that the studies that tested the impact of pharmacogenomics in major depressive disorders and included CYP2D6/CYP2C19 genetic variants largely investigated participants at the beginning of their treatment histories where the impact of pharmacogenomics could be more significant due to the prevailing absence of treatment-resistant depression [7]. This evidence concerns the gene CYP2D6 and major depressive disorder.